ULTRAGENYX PHARM INC
BiotechULTRAGENYX PHARM INC is a biotechnology company with 2 FDA-approved products.
FDA Novel Drug Designations
(2017-2020)ULTRAGENYX PHARM INC at a Glance
- Fast trial execution (30 months median completion)
Upcoming FDA Decisions
Full Calendar →ULTRAGENYX PHARM INC's Key Drugs
ULTRAGENYX PHARM INC's core commercial portfolio centers on DOJOLVI, MEPSEVII — its most strategically important drugs approved in the last 15 years.
ULTRAGENYX PHARM INC's Recent FDA Approvals
New NDA/BLA approvals for ULTRAGENYX PHARM INC over the last two years — novel drugs only, excluding generics and label supplements.
ULTRAGENYX PHARM INC's Therapeutic Areas
Disease areas where ULTRAGENYX PHARM INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ULTRAGENYX PHARM INC Pipeline Snapshot
Active clinical trials for ULTRAGENYX PHARM INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/13 completed
- • Speed: 30 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-11-15
- Latest
- 2023-10-30
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges